Oral Cannabidiol, PTL101, Meets Goals of Phase 1 Study as Possible Spasticity Treatment
News
Results of a Phase 1 clinical trial in healthy volunteers show that PTL101, an oral cannabidiol compound, is a safe and effectively delivered potential treatment of spasticity in multiple sclerosis ... Read more